Analysis of the correlation of RET expression with growth hormone level of patients with growth hormone-secreting pituitary adenoma

doi:10.3877/cma.j.issn.2095-9141.2016.04.002

Abstract

Abstract:

Objective

To investigate the correlation of RET expression with postoperative remission and growth hormone levels of patient with growth hormone-secreting pituitary adenoma(GH-PA).

Methods

Collected and followed up 20 patients (no remission 10, immediate remission 6, delayed remission 4) underwent transsphenoidal endoscopic surgery for GH-PA from from april 2010 to april 2013 in Xijing Hospital, Fourth Military Medical University to measure the changes of GH levels at different time points (before surgery, 1 week, 3month and 1 year after surgery), and the specimen were collected for RET immunohistochemical staining.

Results

The level of RET expression in the delayed remission ones tend to be lower than no remission and immediate remission groups (P<0.05). There is no significant relationship between RET expression and GH levels before, 3 months and 1 year after surgery (P>0.05), however the GH elevation (1 year-1 week) tend to have a positive relationship with RET expression.

Conclusion

RET expression to some degree helps predict delayed remission, and tend to have a positive relationship with GH elevation after surgery in GH-PA patients.

Key words: Growth hormone-secreting pituitary adenoma, Endoscopes, Delayed remission, Long-term curative rate

Qintao Tian, Yue Hei, Xicai Yi, Lizhou Wei, Bochen Wang, Weiping Liu. Analysis of the correlation of RET expression with growth hormone level of patients with growth hormone-secreting pituitary adenoma[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2016, 02(04): 198-201.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2016.04.002

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2016/V02/I04/198

Figures/Tables 4

References 17

[1]	Shin SS,Tormenti MJ,Paluzzi A, et al. Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission[J]. Pituitary, 2013, 16(4): 435-444.
[2]	Schwyzer L,Starke RM,Jane JA, et al. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly[J]. J Neurosurg, 2015, 122(4): 798-802.
[3]	Levi V,Bertani GA,Guastella C, et al. Microscopic versus endoscopic transsphenoidal surgery for pituitary adenoma: analysis of surgical safety in 221 consecutive patients[J]. Clin Otolaryngol, 2016.
[4]	孔博,张文德.内分泌激素水平监测对生长激素型垂体腺瘤患者手术远期疗效的观察[J].中华医学杂志, 2011, 91(31): 2199-2201.
[5]	Yilmaz M,Vural E,Koc K, et al. Cavernous sinus invasion and effect of immunohistochemical features on remission in growth hormone secreting pituitary adenomas[J]. Turk Neurosurg, 2015, 25(3): 380-388.
[6]	Carlsen SM,Svartberg J,Schreiner T, et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure[J]. Clin Endocrinol (Oxf), 2011, 74(6): 736-743.
[7]	Ichihara M,Murakumo Y,Takahashi M. RET and neuroendocrine tumors[J]. Cancer Lett, 2004, 204(2): 197-211.
[8]	Vargiolu M,Fusco D,Kurelac I, et al. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability[J]. J Clin Endocrinol Metab, 2009, 94(7): 2571-2578.
[9]	中华医学会内分泌学分会,中华医学会神经外科学分会,中国垂体腺瘤协作组.中国肢端肥大症诊治指南(2013版)[J].中华医学杂志, 2013, 93(27): 2106-2111.
[10]	Zhou T,Wang F,Meng X, et al. Outcome of endoscopic transsphenoidal surgery in combination with somatostatin analogues in patients with growth hormone producing pituitary adenoma[J]. J Korean Neurosurg Soc, 2014, 56(5): 405-409.
[11]	徐涛,彭林,李昊,等.我国内镜对比显微镜下垂体瘤切除术的更新及累积荟萃分析[J].中华医学杂志, 2015, 95(41): 3378-3381.
[12]	中国垂体腺瘤协作组.中国垂体腺瘤外科治疗专家共识[J].中华医学杂志, 2015, 95(5): 324-329.
[13]	Heliovaara E,Tuupanen S,Ahlsten M, et al. No evidence of RET germline mutations in familial pituitary adenoma[J]. J Mol Endocrinol, 2010, 46(1): 1-8.
[14]	Diaz-Rodriguez E,Garcia-Rendueles AR,Ibanez-Costa A, et al. Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF[J]. Endocrinology, 2014, 155(11): 4329-4340.
[15]	Wang X. Structural studies of GDNF family ligands with their receptors-insights into ligand recognition and activation of receptor tyrosine kinase RET[J]. Biochim Biophys Acta, 2013, 1834(10): 2205-2212.
[16]	Lloyd C,Grossman A. The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas[J]. Endocrine, 2014, 46(3): 387-396.
[17]	Cabanillas ME,Schlumberger M,Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment[J]. Cancer, 2015, 121(16): 2749-2756.

项目	例数(%)	均数	范围
年龄（岁）	?	39.9	19~72
性别（男/女）	13(55%)/7(45%)	?	?
肿瘤直径(mm)	?	21.7	15.1~28.4
住院时间(d)	?	3.6	2~14
手术时长(h)	?	4.1	3.2~6.9
随访时间（年）	?	1.5	0.5~2

项目	例数(%)	均数	范围
年龄（岁）	?	39.9	19~72
性别（男/女）	13(55%)/7(45%)	?	?
肿瘤直径(mm)	?	21.7	15.1~28.4
住院时间(d)	?	3.6	2~14
手术时长(h)	?	4.1	3.2~6.9
随访时间（年）	?	1.5	0.5~2

组别	例数	术前	1周	3个月	1年	GH水平波动	RET表达水平
未缓解组	10	29.59±11.02	11.93±8.05	13.66±6.17	16.88±5.55	4.95±8.81	2.4±1.07^a
即刻缓解组	6	12.78±3.51	1.77±0.08	1.55±0.20	1.50±0.11	0.33±0.14	2.67±0.52^b
延迟缓解组	4	21.50±3.52	7.73±1.94	3.58±2.29	1.20±0.14	-6.8±2.07	1.0±0.82^c*

组别	例数	术前	1周	3个月	1年	GH水平波动	RET表达水平
未缓解组	10	29.59±11.02	11.93±8.05	13.66±6.17	16.88±5.55	4.95±8.81	2.4±1.07^a
即刻缓解组	6	12.78±3.51	1.77±0.08	1.55±0.20	1.50±0.11	0.33±0.14	2.67±0.52^b
延迟缓解组	4	21.50±3.52	7.73±1.94	3.58±2.29	1.20±0.14	-6.8±2.07	1.0±0.82^c*

Please choose a citation manager

Content to export